Novartis AG (LSE:0HKE)
£ 3657.04 0 (0%) Market Cap: 60.95 Bil Enterprise Value: 74.78 Bil PE Ratio: 14.34 PB Ratio: 5.34 GF Score: 77/100

Novartis AG to Discuss the Zolgensma® Update Call Transcript

Aug 07, 2019 / 12:00PM GMT
Samir Shah
Novartis AG - Global Head of IR

Thank you very much, and thank you very much to everybody who's participating on the call today.

Before we begin, I'll just read the safe harbor statement. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Please refer to the company's Form 20-F on file with the U.S. Securities and Exchange Commission for a description of some of these factors.

And with that, I'll hand across to Vas.

Vasant Narasimhan
Novartis AG - CEO

Thank you, Samir. And thanks for everyone for joining today's call. We're here to provide you an update and answer your questions regarding FDA's recent communication on Zolgensma. I'll go through a few opening points, and then we'll open the line for questions.

First and foremost, we are fully confident in the safety, quality and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot